The Division of Research encompasses multiple initiatives as follows:
- Basic immunology research focusing on the biology of graft-versus-host disease (GVHD), a common, potentially fatal complication of stem cell transplantation. Our scientists were responsible for some of the breakthrough discoveries in GVHD over the past 25 years, as well as studies of the immunological repertoire post stem cell transplantation. In addition, our scientists showed the benefit of modifying donor T-cells (TH-2 amplification) to reduce incidence of GVHD and improve anti tumor effect. The immunology research lab at HUMC has ongoing collaboration with the National Institute of Health, the Dana Farber Cancer Center in Boston, and the Multiple Myeloma Research Foundation.
- Genetics initiative: our Tissue Repository has now collected thousands of samples from over 3,500 patients since inception. Ongoing research has focused on the characterization of biomarkers, particularly in mantle cell lymphoma and Hodgkin lymphoma and other tumors through external collaborations.
- Ex-vivo primary culture for expansion of tumor cells. This program, particularly in collaboration with the Stevens Institute, has established the ability to grow multiple myeloma cells in a micro device that might offer an opportunity for drug testing, as well as further understanding the biology of multiple myeloma cells.
Our clinical research team is the largest in New Jersey, with over 65 dedicated staff for adult oncology research only. We have over 300 ongoing clinical trials, including a dedicated Phase I unit (with multiple first in-human ongoing studies) to provide our patients with crucial novel options in a rapidly changing environment with thousands of novel therapies on the horizon.